PMID- 20824398
OWN - NLM
STAT- MEDLINE
DCOM- 20110331
LR  - 20151119
IS  - 1864-6433 (Electronic)
IS  - 0914-7187 (Linking)
VI  - 24
IP  - 9
DP  - 2010 Nov
TI  - Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in 
      heart failure patients with preserved ejection fraction.
PG  - 679-86
LID - 10.1007/s12149-010-0409-3 [doi]
AB  - OBJECTIVE: Iodine-123-metaiodobenzylguanidine ((123)I-MIBG) has been used to 
      assess the function of the cardiac sympathetic nervous system in patients with 
      chronic heart failure (HF). The usefulness of (123)I-MIBG imaging for evaluating 
      patients with heart failure with preserved ejection fraction (HFPEF) has not been 
      established. METHODS: We performed (123)I-MIBG scintigraphy and echocardiography 
      and measured the plasma brain natriuretic peptide (BNP) levels of 117 consecutive 
      HF patients (64 men, mean age 66 +/- 14 years) with a left ventricular ejection 
      fraction (LVEF) of >/=50% who were admitted to our hospital. Patients were divided 
      into 2 groups according to the New York Heart Association (NYHA) functional 
      class. RESULTS: The (123)I-MIBG delayed heart-to-mediastinum (H/M) ratio was 
      significantly lower, and the washout rate (WR) was higher in patients with HFPEF 
      with advanced NYHA functional class (NYHA functional class I and II vs. III: 
      1.90 +/- 0.34 vs. 1.49 +/- 0.32, p < 0.0001; 25.9 +/- 13.4 vs. 46.9 +/- 16.3%, 
      p < 0.0001, respectively). On the other hand, the (123)I-MIBG WR was not 
      correlated with LVEF and had a weak correlation with plasma BNP levels 
      (R = 0.207, p = 0.0346). Moreover, patients with a high (123)I-MIBG WR showed a 
      poor clinical outcome (p = 0.0033). CONCLUSIONS: (123)I-MIBG imaging provides 
      independent prognostic information in patients with HFPEF.
FAU - Katoh, Shigehiko
AU  - Katoh S
AD  - Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School 
      of Medicine, 2-2-2 Iida-Nishi, Yamagata, Japan.
FAU - Shishido, Tetsuro
AU  - Shishido T
FAU - Kutsuzawa, Daisuke
AU  - Kutsuzawa D
FAU - Arimoto, Takanori
AU  - Arimoto T
FAU - Netsu, Shunsuke
AU  - Netsu S
FAU - Funayama, Akira
AU  - Funayama A
FAU - Ishino, Mitsunori
AU  - Ishino M
FAU - Niizeki, Takeshi
AU  - Niizeki T
FAU - Nishiyama, Satoshi
AU  - Nishiyama S
FAU - Takahashi, Hiroki
AU  - Takahashi H
FAU - Miyashita, Takehiko
AU  - Miyashita T
FAU - Miyamoto, Takuya
AU  - Miyamoto T
FAU - Nitobe, Joji
AU  - Nitobe J
FAU - Watanabe, Tetsu
AU  - Watanabe T
FAU - Kubota, Isao
AU  - Kubota I
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100908
PL  - Japan
TA  - Ann Nucl Med
JT  - Annals of nuclear medicine
JID - 8913398
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
MH  - *3-Iodobenzylguanidine/pharmacokinetics
MH  - Aged
MH  - *Diagnostic Imaging
MH  - Female
MH  - Heart Failure/blood/*diagnosis/metabolism/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Prognosis
MH  - Risk
MH  - *Stroke Volume
EDAT- 2010/09/09 06:00
MHDA- 2011/04/01 06:00
CRDT- 2010/09/09 06:00
PHST- 2010/04/28 00:00 [received]
PHST- 2010/07/30 00:00 [accepted]
PHST- 2010/09/09 06:00 [entrez]
PHST- 2010/09/09 06:00 [pubmed]
PHST- 2011/04/01 06:00 [medline]
AID - 10.1007/s12149-010-0409-3 [doi]
PST - ppublish
SO  - Ann Nucl Med. 2010 Nov;24(9):679-86. doi: 10.1007/s12149-010-0409-3. Epub 2010 
      Sep 8.